Silexion Therapeutics CORP (SLXNW) — SEC Filings

Overview

Silexion Therapeutics CORP (SLXNW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 16, 2025: Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on December 16, 2025. The filing indicates a change in the company's name and potentially its business focus, as it is now listed under "BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)" with SIC code 2836. The company is incorpora

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 4 bearish, 44 neutral, 2 mixed. The dominant filing sentiment for Silexion Therapeutics CORP is neutral.

Filing Type Overview

Silexion Therapeutics CORP (SLXNW) has filed 37 8-K, 2 10-Q, 3 S-1, 3 DEFA14A, 2 DEF 14A, 1 8-K/A, 1 S-1/A, 1 10-K with the SEC between Nov 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

• Silexion Therapeutics Corp. Files 8-K — 8-K · Dec 16, 2025 Risk: medium
  Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on December 16, 2025. The filing indicates a change in the company's name and potentially
• Silexion Therapeutics Files 8-K — 8-K · Dec 2, 2025 Risk: low
  Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on December 2, 2025, reporting under Regulation FD and including financial statements and
• Silexion Therapeutics Files 8-K — 8-K · Nov 25, 2025 Risk: low
  Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on November 25, 2025, reporting under Regulation FD and including financial statements an
• Silexion Boosts Cash, Equity Amidst R&D Cuts and Reverse Splits — 10-Q · Nov 12, 2025 Risk: high
  Silexion Therapeutics Corp (SLXNW) reported a significant increase in cash and cash equivalents to $9.243 million as of September 30, 2025, up from $1.187 milli
• Silexion Therapeutics Files 8-K — 8-K · Sep 30, 2025 Risk: low
  Silexion Therapeutics Corp. filed an 8-K on September 30, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, form
• Silexion Therapeutics Corp. Files 8-K for Material Agreement — 8-K · Sep 26, 2025 Risk: medium
  Silexion Therapeutics Corp. (formerly Biomotion Sciences) entered into a material definitive agreement on September 26, 2025. The company, incorporated in the C
• Silexion Therapeutics to Acquire 03 Life Sciences — 8-K · Sep 25, 2025 Risk: medium
  Silexion Therapeutics Corp. announced on September 23, 2025, that it has entered into a definitive agreement to acquire all outstanding shares of 03 Life Scienc
• Silexion Therapeutics Reports Equity Issuance — 8-K · Sep 15, 2025 Risk: medium
  Silexion Therapeutics Corp. reported on September 15, 2025, regarding unregistered sales of equity securities and other events. The company, formerly known as B
• Silexion Therapeutics Corp. Files Material Definitive Agreement — 8-K · Sep 12, 2025 Risk: medium
  Silexion Therapeutics Corp. entered into a material definitive agreement on September 11, 2025. The company, formerly known as Biomotion Sciences, is incorporat
• Silexion Therapeutics Files 8-K — 8-K · Sep 11, 2025 Risk: low
  Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on September 11, 2025, reporting under Regulation FD and including financial statements a
• Silexion Launches Best-Efforts Offering Amidst Reverse Splits — S-1 · Sep 5, 2025 Risk: high
  Silexion Therapeutics Corp (SLXNW) is conducting a best-efforts offering of up to 832,177 ordinary shares, accompanied by Series A and Series B ordinary warrant
• Silexion Therapeutics Corp. Files 8-K — 8-K · Sep 4, 2025 Risk: low
  Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on September 4, 2025, reporting on events that occurred on the same date. The filing indi
• Silexion Therapeutics Files 8-K — 8-K · Sep 2, 2025 Risk: low
  Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on September 2, 2025, reporting on events as of the same date. The filing indicates the c
• Silexion Files S-1 for Resale of 314,859 Shares Amidst Funding Needs — S-1 · Aug 26, 2025 Risk: high
  Silexion Therapeutics Corp (SLXNW) is a clinical-stage oncology biotechnology company focused on developing RNA-interference therapeutics for KRAS-driven cancer
• Silexion Therapeutics Files 8-K — 8-K · Aug 20, 2025 Risk: low
  Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on August 20, 2025, reporting other events and financial statements. The company, incorpo
• Silexion Therapeutics Files 8-K with Corporate Updates — 8-K · Aug 19, 2025 Risk: low
  Silexion Therapeutics Corp. filed an 8-K on August 19, 2025, reporting on amendments to its articles of incorporation or bylaws, submission of matters to a vote
• Silexion Therapeutics Files Proxy Materials — DEFA14A · Aug 12, 2025 Risk: low
  Silexion Therapeutics Corp. filed a Definitive Additional Materials proxy statement on August 12, 2025. The company, formerly known as Biomotion Sciences until
• Silexion Therapeutics Files 8-K: Agreements & Equity Sales — 8-K · Aug 1, 2025 Risk: medium
  Silexion Therapeutics Corp. (formerly Biomotion Sciences) reported on August 1, 2025, regarding a material definitive agreement, unregistered sales of equity se
• Silexion Seeks Shareholder Nod for 500%+ Capital Increase — DEF 14A · Jul 31, 2025 Risk: medium
  Silexion Therapeutics Corp (SLXNW) is seeking shareholder approval to increase its authorized share capital from US$20,000, divided into 1,481,482 ordinary shar
• Silexion Therapeutics to be Acquired by 03 Life Sciences — 8-K · Jul 29, 2025 Risk: medium
  Silexion Therapeutics Corp. announced on July 29, 2025, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction is e
• Silexion Therapeutics Faces Delisting Notice — 8-K · Jul 21, 2025 Risk: high
  Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on July 21, 2025, reporting a notice of delisting or failure to satisfy a continued listi
• Silexion Therapeutics Files 8-K, Former Biomotion Sciences — 8-K · Jul 16, 2025 Risk: low
  Silexion Therapeutics Corp. filed an 8-K on July 16, 2025, reporting on other events and financial statements. The company, formerly known as Biomotion Sciences
• Silexion Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · Jul 14, 2025 Risk: low
  Silexion Therapeutics Corp. filed an 8-K on July 14, 2025, reporting on a submission of matters to a vote of security holders. The company, formerly known as Bi
• Silexion Therapeutics Files 8-K — 8-K · Jul 9, 2025 Risk: low
  Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on July 9, 2025, reporting on its ordinary shares and warrants. The company, incorporated
• Silexion Therapeutics Files 8-K/A Amendment — 8-K/A · Jul 8, 2025 Risk: low
  Silexion Therapeutics Corp. filed an amendment (8-K/A) on July 8, 2025, to a previous report. The amendment pertains to "Other Events" and was filed as of July
• Silexion Therapeutics Files Proxy Statement — DEFA14A · Jul 7, 2025 Risk: low
  Silexion Therapeutics Corp filed a Definitive Additional Materials proxy statement on July 7, 2025. The company, formerly known as Biomotion Sciences until May
• Silexion Therapeutics Files Proxy Materials — DEFA14A · Jun 23, 2025 Risk: low
  Silexion Therapeutics Corp filed a Definitive Additional Materials proxy statement on June 23, 2025. This filing relates to the company's proxy materials, indic
• Silexion Sets July 7 Shareholder Meeting for Director, Auditor Votes — DEF 14A · Jun 16, 2025 Risk: low
  Silexion Therapeutics Corp (SLXNW) filed a Definitive Proxy Statement (DEF 14A) on June 16, 2025, for its annual general meeting scheduled for July 7, 2025. The
• Silexion Therapeutics Raises $1.3M in Share Sale — 8-K · Jun 3, 2025 Risk: medium
  Silexion Therapeutics Corp. announced on June 3, 2025, that it has entered into a securities purchase agreement. The agreement involves the sale of 1,150,000 or
• Silexion Therapeutics Files 8-K on Share and Warrant Activity — 8-K · May 29, 2025 Risk: low
  Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on May 29, 2025, reporting on events related to its ordinary shares and warrants. The com
• Silexion Therapeutics Receives NASDAQ Delisting Notice — 8-K · May 23, 2025 Risk: high
  Silexion Therapeutics Corp. announced on May 23, 2025, that it received a notice from NASDAQ on May 22, 2025, indicating a failure to meet a continued listing r
• Silexion Therapeutics Files 8-K — 8-K · May 21, 2025 Risk: low
  Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on May 21, 2025, reporting on financial statements and exhibits. The company, incorporate
• Silexion Therapeutics Files 10-Q Post Reverse Split — 10-Q · May 13, 2025 Risk: medium
  Silexion Therapeutics Corp. filed a 10-Q for the period ending March 31, 2025. The company, formerly known as Biomotion Sciences, reported financial results aft
• Silexion Therapeutics Files 8-K with Financials — 8-K · Apr 23, 2025 Risk: low
  Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on April 23, 2025, reporting on financial statements and exhibits. The company, incorpora
• Silexion Therapeutics Files 8-K, Notes Warrants — 8-K · Mar 28, 2025 Risk: low
  Silexion Therapeutics Corp. filed an 8-K on March 28, 2025, reporting on other events and financial statements. The company, formerly known as Biomotion Science
• Silexion Therapeutics Files S-1/A, Reverse Stock Split — S-1/A · Mar 27, 2025 Risk: medium
  Silexion Therapeutics Corp. filed an S-1/A on March 27, 2025, to update its registration statement. The company, formerly known as Biomotion Sciences until May
• 10-K Filing — 10-K · Mar 18, 2025
• Silexion Therapeutics Corp. Files 8-K for Material Definitive Agreement — 8-K · Mar 14, 2025 Risk: medium
  Silexion Therapeutics Corp. (formerly Biomotion Sciences) announced on March 14, 2025, that it entered into a material definitive agreement. The company, incorp
• Silexion Therapeutics Files 8-K with Financials & Warrants — 8-K · Mar 5, 2025 Risk: low
  Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on March 5, 2025, reporting on financial statements and exhibits. The company, incorporat
• Silexion Therapeutics Files S-1 — S-1 · Feb 12, 2025 Risk: medium
  Silexion Therapeutics Corp. filed an S-1 form on February 12, 2025, detailing its business operations. The company, formerly known as Biomotion Sciences until a
• Silexion Therapeutics Corp. Files 8-K: Material Agreement & Equity Sales — 8-K · Jan 30, 2025 Risk: medium
  On January 29, 2025, Silexion Therapeutics Corp. entered into a material definitive agreement. The company also reported on unregistered sales of equity securit
• Silexion Therapeutics Files 8-K on Warrants — 8-K · Jan 28, 2025 Risk: low
  Silexion Therapeutics Corp. (formerly Biomotion Sciences) announced on January 28, 2025, that it has filed a Form 8-K. The company, incorporated in the Cayman I
• Silexion Therapeutics Corp. Enters Material Definitive Agreement — 8-K · Jan 17, 2025 Risk: medium
  On January 15, 2025, Silexion Therapeutics Corp. entered into a material definitive agreement. The company, formerly known as Biomotion Sciences until May 6, 20
• Silexion Therapeutics Corp. Files 8-K — 8-K · Jan 15, 2025 Risk: low
  Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on January 15, 2025, reporting on its corporate actions. The company, incorporated in the
• Silexion Therapeutics Files 8-K on Financials — 8-K · Jan 14, 2025 Risk: low
  Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on January 14, 2025, reporting on its results of operations and financial condition. The
• Silexion Therapeutics Files 8-K on Shares and Warrants — 8-K · Dec 17, 2024 Risk: low
  Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on December 17, 2024, reporting on ordinary shares and warrants. The company, incorporate
• Silexion Therapeutics Announces Warrant Exercise Agreement — 8-K · Dec 16, 2024 Risk: low
  Silexion Therapeutics Corp. announced on December 16, 2024, that it has entered into a warrant exercise agreement. This agreement allows for the exercise of war
• Silexion Therapeutics Appoints New CMO, Board Member — 8-K · Dec 10, 2024 Risk: medium
  On December 10, 2024, Silexion Therapeutics Corp. announced the appointment of Dr. Yaron Paz as Chief Medical Officer and Dr. Shimon Eckhouse as a new board mem
• Silexion Therapeutics Corp. Files 8-K for Security Holder Rights — 8-K · Nov 29, 2024 Risk: medium
  Silexion Therapeutics Corp. (formerly Biomotion Sciences) announced on November 27, 2024, a material modification to the rights of its security holders. This fi
• Silexion Therapeutics Files 8-K on Warrants — 8-K · Nov 27, 2024 Risk: low
  Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on November 27, 2024, reporting on warrants exercisable for ordinary shares at $1.150 per

Related Companies

SLXN

Frequently Asked Questions